August 20, 2014 10:44 PM ET

Pharmaceuticals

Company Overview of TaiGen Biotechnology Co., Ltd.

Company Overview

TaiGen Biotechnology Co., Ltd., a pharmaceutical company, engages in the development of novel therapeutics for infectious diseases, cancer, and diabetes. It offers Nemonoxacina, a drug-resistant anti-infection drug for community acquired pneumonia, diabetic foot infection, skin infections, and nosocomial pneumonia; and stem cell mobilizer products to mobilize stem cells and progenitor cells from the bone marrow into peripheral circulation, as well as for chemosensitization treatment of leukemia patients. The company also provides hepatitis C virus protease inhibitors, anti-influenza drugs, anti-gram negative drugs, and bacteria drugs. TaiGen Biotechnology Co., Ltd. was founded in 2001 and is...

138 Shin Ming Road

7th Floor

Neihu Dist.

Taipei,  114

Taiwan

Founded in 2001

Phone:

886 2 8177 7072

Fax:

886 2 2796 3606

Key Executives for TaiGen Biotechnology Co., Ltd.

Chief Financial Officer
Age: 47
Vice President of Corporate Operations
Senior Vice President of Research
Senior Vice President of Product Development and Marketing General Manager of Taigen Beijing
Compensation as of Fiscal Year 2014.

TaiGen Biotechnology Co., Ltd. Key Developments

TaiGen Biotechnology Co., Ltd. Presents at BIO Asia International Conference, Apr-09-2014 01:00 PM

TaiGen Biotechnology Co., Ltd. Presents at BIO Asia International Conference, Apr-09-2014 01:00 PM. Venue: Grand Hyatt, Tokyo, Tokyo, Japan.

TaiGen Biotechnology Co., Ltd. Presents at Bank of America Merrill Lynch - Taiwan, Technology & Beyond 2014, Mar-21-2014 03:15 PM

TaiGen Biotechnology Co., Ltd. Presents at Bank of America Merrill Lynch - Taiwan, Technology & Beyond 2014, Mar-21-2014 03:15 PM. Venue: Shangri-La's Far Eastern Plaza Hotel, Taipei, Taiwan.

TaiGen Biotechnology Signs Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R))

TaiGen Biotechnology Company, Limited announced that they have signed an exclusive agreement with R-Pharm to develop and commercialize nemonoxacin (Taigexyn(R)) in the Russian Federation, Turkey and other members of the Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria. Under the terms of the agreement, R-Pharm will be responsible for the development, registration and commercialization of nemonoxacin in these territories and assume all associated costs. In exchange for the exclusive rights, TaiGen will receive an upfront payment and is eligible for additional regulatory and commercial milestones as well as royalties on product sales in the future.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TaiGen Biotechnology Co., Ltd., please visit www.taigenbiotech.com.tw. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.